PSMA靶向放射性药物:成像与治疗综述
本综述概述了前列腺特异性膜抗原(PSMA)靶向放射性药物在成像与治疗中的应用。PSMA在前列腺癌细胞上过表达,尤其见于去势抵抗性、晚期和转移性疾病。文章总结了已广泛临床应用的PSMA小分子抑制剂类示踪剂特性,并讨论了增加血浆蛋白结合等新概念。
要点
- PSMA是核医学中极具前景的分子靶点,其过表达与前列腺癌分期和分级相关。
- 小分子PSMA抑制剂因肿瘤摄取快、排泄迅速,已成为近十年研究焦点。
- 综述覆盖已广泛临床应用的PSMA放射性药物及增加血浆蛋白结合等新概念。
核心结论
- PSMA已成为核医学中最有前景的分子靶点之一,其在前列腺癌细胞上的过表达与肿瘤分期和分级成比例,尤其在非雄激素依赖性、晚期和转移性疾病中。
- 小分子PSMA抑制剂因肿瘤摄取快和排泄迅速的优势,已取代单克隆抗体成为近十年的研究焦点,并开发出多种用于放射配体成像、放射配体治疗或放射性引导手术的示踪剂。
研究设计与样本
- 本文为综述,旨在概述已广泛临床应用的PSMA放射性药物的具体特性,并讨论近期引入的新概念。
主要发现
- PSMA在前列腺癌细胞上过表达,与肿瘤分期和分级成比例,尤其在非雄激素依赖性、晚期和转移性疾病中。
- 多种PSMA靶向示踪剂已开发并转入临床应用,用于前列腺癌的放射配体成像、放射配体治疗或放射性引导手术。
- 单克隆抗体是最早研究的PSMA靶向探针,但小分子抑制剂因肿瘤摄取快和排泄迅速的优势成为近十年研究焦点。
- 已提及的小分子PSMA抑制剂包括[18F]FDCFPyL、[18F]PSMA-1007、[68Ga]PSMA-HBED、[177Lu]PSMA-617、[177Lu]PSMA-I&T、[99mTc]MIP-1404和[99mTc]PSMA I&S等。
- 综述还讨论了增加血浆蛋白结合的PSMA示踪剂等新引入的概念。
临床怎么用
- 临床可依据本综述了解已广泛应用的PSMA放射性药物特性,用于前列腺癌的放射配体成像、放射配体治疗或放射性引导手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As described in more detail in other contributions in this issue of Seminars in Nuclear Medicine, prostate-specific membrane antigen (PSMA) has become one of the most promising molecular targets in nuclear medicine. Due to its overexpression on prostate cancer cells in proportion to the stage and grade of tumour progression, especially in androgen-independent, advanced and metastatic disease, various tracers for the detection and treatment of prostate cancer by means of radioligand imaging, radioligand therapy or radioguided surgery have been developed and transferred to clinical applications. Even though monoclonal antibodies were investigated and introduced as first PSMA-targeted probes, the inherent advantage of fast tumour uptake and rapid excretion of small molecules has shifted the research focus during the last decade to low molecular weight inhibitors with high affinity to PSMA, such as [18F]FDCFPyL, [18F]PSMA-1007, [68Ga]PSMA-HBED, [177Lu]PSMA-617, [177Lu]PSMA-I&T, [99mTc]MIP-1404 or [99mTc]PSMA I&S, to mention only a few. Due to the plethora of such PSMA probes described during the last years, this review aims to give an overview over the specific characteristics of those radiopharmaceuticals that have already found widespread clinical application. In addition, recently introduced concepts such as PSMA-tracers with increased plasma protein binding, are discussed.
引用
- Wester HJ, Schottelius M. PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy. Semin Nucl Med. 2019. PMID: 31227053. doi:10.1053/j.semnuclmed.2019.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。